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882-1 Anglo-Scandinavian Cardiac Outcomes Trial – Lipid-
Lowering Arm (ASCOT-LLA): Results in the Subgroup of 
Patients With Diabetes
Peter S. Sever, Bjorn Dahlof, Neil Poulter, Hans Wedel, for the ASCOT Steering 
Committee and ASCOT Investigators, Imperial College, London, United Kingdom, 
Sahlgrenska University Hospital, Gothenburg, Sweden
Of 10,305 patients randomised to either atorvastatin (10mg) or placebo in ASCOT-LLA,
approximately 25% (n=2532) fulfilled pre-defined criteria for a diagnosis of type-2 diabe-
tes mellitus. All patients were hypertensive (aged 40-79 years) with at least two additional
risk factors for cardiovascular disease, and had non-fasting total cholesterol levels of
6.5mmol/L (250mg%) or less.
ASCOT-LLA was stopped early after a median follow-up period of 3.3 years, owing to a
36% reduction in non-fatal myocardial infarction and fatal coronary heart disease (p =
0.0005) and a 27% reduction in fatal and non-fatal stroke (p = 0.02).
In the prespecified subgroup of patients with type-2 diabetes mellitus, among those allo-
cated to atorvastatin, LDL-cholesterol was lowered by an average of about 1.0mmol/L
(40mg%) compared with placebo, and there was a 23% reduction in the numbers of total
cardiovascular events (hazard ratio 0.77, CI 0.61-0.98; p = 0.036).
The analysis was not sufficiently powered to detect reductions in individual components
of the composite endpoint. All coronary events were reduced by 17% and fatal and non-
fatal stroke by 33%. These reductions were not significant, however, there was no signifi-
cant heterogeneity amongst subgroups of patients in ASCOT-LLA. These results, in a
lower risk diabetic population than studied in the Heart Protection Study, extend the evi-
dence for cardiovascular benefits from lipid-lowering with statins in patients with type-2
diabetes mellitus.
10:45 a.m.
882-2 Effects of Avasimibe on Coronary Atherosclerosis 
Assessed by Intravascular Ultrasound
Jean-Claude Tardif, Jean Gregoire, Jacques Lesperance, Josep Rodes, Todd Anderson, 
Eric Cohen, Olivier Bertrand, Michel Lemay, Fernando Alfonso, Francois Reeves, 
Lawrence Title, Alita Hassan, Richard McLain, Milton Pressler, Philippe L. L'Allier, 
Montreal Heart Institute, Montreal, PQ, Canada
Background: Inhibition of the acyl-CoA: cholesterol-acyltransferase (ACAT) enzyme in
the arterial wall may prevent excess accumulation of cholesteryl esters in macrophages.
The ACAT inhibitor avasimibe has been shown to reduce atherosclerotic plaque in animal
models. Methods: A-PLUS was an international, multicenter, double-blind, placebo-con-
trolled, randomized trial that assessed the effect of avasimibe at 50, 250 and 750 mg QD
dosages on the progression of coronary atherosclerosis as assessed by intravascular
ultrasound (IVUS) and quantitative coronary angiography (QCA). All patients (n=639)
received background lipid-lowering therapy if necessary to reach a target baseline LDL
level below 3.2 mmol/L (125 mg/dl). IVUS and coronary angiography were performed at
baseline and repeated after up to 2 years of treatment. The primary study endpoint was
the change from baseline in plaque volume in a 30-mm coronary artery segment
assessed by 3-D IVUS. Results: Approximately equal percentages of patients across
treatment groups received concurrent statin therapy (87-89%). The mean total plaque
volume at baseline was approximately 200 mm3. The least square mean change in
plaque volume from baseline to end of treatment was 0.7 mm3 for the placebo group, 7.7
mm3 for the avasimibe 50 mg group, 4.1 mm3 for the 250 mg group and 4.8 mm3 for the
750 mg group. Treatment comparisons of the difference in plaque volume for avasimibe
50, 250 and 750 mg from baseline to end of treatment were not statistically significant
versus placebo (adjusted p=0.17 (unadjusted p=0.0575), 0.37 and 0.37, respectively).
There were likewise no significant differences in total lumen volume, total vessel volume,
nor angiographically (QCA) determined progression. Avasimibe was well tolerated during
chronic use. Conclusion: Avasimibe did not significantly alter coronary atherosclerotic
plaque burden over up to 2 years of treatment as assessed by IVUS and coronary
angiography.
11:00 a.m.
882-3 Effects of Pravastatin on Lipoproteins and Endothelial 
Function in Patients Receiving Human 
Immunodeficiency Virus Protease Inhibitors
James H. Stein, Michelle A. Merwood, Jennifer L. Bellehumeur, Susan E. Aeschlimann, 
Claudia E. Korcarz, Gail L. Underbakke, Maureen E. Mays, James M. Sosman, 
University of Wisconsin Medical School, Madison, WI
Background
Although recommended as initial therapy for dyslipidemic patients taking human immun-
odeficiency virus protease inhibitors (HIV PIs), pravastatin's effects on lipoproteins and
arterial reactivity have not been elucidated. The purpose of this study was to determine
the effects of pravastatin on lipoprotein subfractions and endothelial function in dyslipi-
demic patients receiving HIV PIs.
Methods
This was a placebo-controlled, double-blind, crossover study comparing pravastatin (40
mg) to placebo in 20 non-diabetic, HIV-positive individuals taking PIs. Lipoprotein sub-
fractions were measured by nuclear magnetic resonance spectroscopic analysis. Flow-
mediated vasodilation (FMD) of the brachial artery was evaluated using high-resolution
ultrasound.
Results
At baseline, subjects had (mean ± standard error): hypercholesterolemia (total choles-
terol 216 ± 15 mg/dl), hypertriglyceridemia (335 ± 59 mg/dl), and low high-density lipo-
protein cholesterol (HDL-C, 36 ± 3 mg/dl) with increased non-HDL-C levels (180 ± 14 mg/
dl). Subjects had increased concentrations of low-density lipoprotein (LDL) particles
(1756 ± 180 nmol/l), which were small (19.9 ± 0.2 nm), low concentrations of large HDL
(12 ± 2 mg/dl), and high concentrations of large very low-density lipoproteins (VLDL)
(168 ± 51 mg/dl). FMD was impaired (4.5 ± 1.1%). Compared to placebo, pravastatin
reduced total cholesterol by 18% (p<0.001), LDL-C by 20% (p=0.022), and non-HDL-C
by 22% (p<0.001). Pravastatin therapy was associated with reductions in LDL (-21%,
p=0.030), small LDL (-27%, p=0.100), and small VLDL (-45%, p=0.023), and improved
FMD (0.7 ± 0.6%, p=0.080). Predictors of improved FMD with pravastatin included glu-
cose (p=0.004), intermediate-density lipoprotein (p=0.001), and HDL-C (p=0.042) levels
(r2adjusted = 66.4%, p<0.001).
Conclusions
This is the first double-blind, placebo-controlled study of the effects of statin therapy on
lipoprotein subfractions and endothelial function in individuals taking HIV PIs. Pravastatin
therapy was associated with improved endothelial function and lower concentrations of
atherogenic lipoproteins, particularly those most associated with future coronary events.
11:15 a.m.
882-4 Active Hydroxy Metabolite of Atorvastatin Increases 
Resistance of Human Low-Density Lipoproteins to 
Oxidative Modification
Mary F. Walter, Robert F. Jacob, Yujia Weng, R. Preston Mason, Elucida Research, 
Beverly, MA, Harvard Medical School, Boston, MA
BACKGROUND: Modified low-density lipoprotein (LDL) contributes to endothelial dys-
function, an early event in atherogenesis. This study tested the comparative, non-enzy-
matic effects of hydroxy-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors
(statins) on the resistance of human LDL to oxidative modification.
METHODS: The dose-dependent effects of widely-used statins (atorvastatin, lovastatin,
pravastatin, simvastatin, and rosuvastatin) on the susceptibility of LDL to oxidative modi-
fication were determined by measurements of copper-induced conjugated diene and
malondialdehyde (MDA) formation. The antioxidant potential of these compounds was
measured using the oxygen radical absorbance capacity (ORAC) assay. The activity of
the statins was correlated with molecular lipid interactions as determined by small angle
x-ray diffraction approaches.
RESULTS: Copper-induced conjugated diene formation in human LDL was dramatically
inhibited by the active, hydroxylated metabolite of atorvastatin (ATM) (54%, P<0.01) and,
to a much lesser extent, by the parent atorvastatin compound (12%, P<0.01) at 100 nM.
A small antioxidant effect was observed for lovastatin (11%, P<0.01), whereas pravasta-
tin, simvastatin, and rosuvastatin did not have any protective activities. Consistent with
these observations, ATM inhibited MDA formation in a dose-dependent fashion and
yielded an ORAC value 10 times greater than that of the standard, Trolox. Small angle x-
ray diffraction analyses and molecular modeling calculations indicated that ATM interacts
with phospholipid molecules such that the hydroxyl function unique to the metabolite is in
close proximity (<5 Å) to susceptible acyl chain double bonds.
CONCLUSION: ATM increases the resistance of LDL to oxidative modification at phar-
macologic concentrations due to specific physico-chemical interactions with lipid mole-
cules, independently of HMG-CoA interactions. The o-hydroxy group unique to ATM is
capable of quenching free radical reactions by proton-donation mechanisms, unlike the
parent compound or other statins.
11:30 a.m.
882-5 Impact of Food and Drug Administration Safety 
Relabeling of Simvastatin Within a Large Health Care 
System
Allen J. Taylor, Jeannie Lee, Karen A. Grace, Walter Reed Army Medical Center, 
Washington, DC
Background: The voluntary safety relabeling of simvastatin placed new constraints on the
use and dose of simvastatin co-prescribed with other commonly used cardiovascular
agents including niacin, fibrates, calcium channel blockers, and amiodarone. We exam-
ined the impact of this change within a large health care system. Methods: We performed
a computerized search within the Walter Reed Health Care System of all patients pre-
scribed simvastatin between September 2001 and 2002. Among over 2000 patients iden-
tified, a random sample (random number seed) of 500 patients was selected. Electronic
pharmacy and laboratory records were reviewed to determine the prevalence of potential
drug interactions, and the frequency of therapeutic drug monitoring. Results: Among this
population of individuals treated with simvastatin (predominately male, mean age 65),
36% were treated with high dose (>20 mg/d) simvastatin. Potential CYP3A4 drug interac-
tions were very common, with 87.9% having concomitant therapy with at least one poten-
tially interacting inhibitor of the CYP3A4 enzyme system. This included amiodarone or
verapamil in 55% (of whom 1 in 4 exceeded the recommended maximum simvastatin
dose of 20 mg/d) and niacin/fibrates/other in 35%. Only 1 in 5 patients had laboratory
